June 6, 2018
During the third week of May, the ITN gathered in Seattle with members of the NSC, NIAID, and Rho for ITN’s first Network Steering Committee meeting of 2018. We accomplished quite a bit in our short time together.
The recommendations from the NSC to approve moving forward with the Treg Autoimmune Hepatitis protocol (Levitsky), anti-IL15 for the treatment of vitiligo (Harris), dupilumab plus grass (Durham), and the teplizumab / RN168 combination in T1D were all approved by the Network Executive Committee.
We have posted the presentations for these studies as well as the presentations for the tclinical and mechanistic studies from the ITN portfolio on our document portal.
As you know all of the meeting material is confidential and may not be redistributed.
More Information